Current concepts in the diagnosis and management of left ventricular assist device infections

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 2, 2013, Pages 201-210

  Nienaber, Juhsien ^a   Wilhelm, Mark P ^a   Sohail, M Rizwan ^a  

^a Mayo Clinic   (United States)

Author keywords

bloodstream infection; diagnosis; driveline; endocarditis; heart failure; infection; left ventricular assist device; management; microbiology; pump pocket

Indexed keywords

ANTIBIOTIC AGENT; CEFAZOLIN; FLUCONAZOLE; NYSTATIN; VANCOMYCIN;

BLOODSTREAM INFECTION; CANDIDA; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEVICE INFECTION; DEVICE SAFETY; DISEASE ASSOCIATION; DRUG RESPONSE; ECHOGRAPHY; ENDOCARDITIS; ENTEROBACTER; ENTEROCOCCUS; HUMAN; IMPLANTATION; INCIDENCE; INFECTION PREVENTION; INFECTION RATE; KLEBSIELLA; LEFT VENTRICULAR ASSIST DEVICE; MEDICAL DECISION MAKING; NONHUMAN; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PSEUDOMONAS AERUGINOSA; REVIEW; SERRATIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; SYNDROME DELINEATION;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ENDOCARDITIS; HEART-ASSIST DEVICES; HUMANS; PROSTHESIS-RELATED INFECTIONS; RISK FACTORS;

EID: 84873910213     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.163     Document Type: Review

References (49)

1. Lloyd-Jones D, Adams R, Carnethon M et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119(3), 480-486 (2009).
2. Ammar KA, Jacobsen SJ, Mahoney DW et al. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/ American Heart Association heart failure staging criteria in the community. Circulation 115(12), 1563-1570 (2007).
3. Cai J, Terasaki PI. Heart transplantation in the United States 2004. Clin. Transpl. 331-344 (2004).
4. Holman WL, Park SJ, Long JW et al.; REMATCH Investigators. Infection in permanent circulatory support: experience from the REMATCH trial. J. Heart Lung Transplant. 23(12), 1359-1365 (2004).
5. Kirklin JK, Naftel DC, Kormos RL et al. Second INTERMACS annual report: more than 1,000 primary left ventricular assist device implants. J. Heart Lung Transplant. 29(1), 1-10 (2010).
6. Krishnamani R, DeNofrio D, Konstam MA. Emerging ventricular assist devices for long-term cardiac support. Nat. Rev. Cardiol. 7(2), 71-76 (2010).
7. Baddour LM, Bettmann MA, Bolger AF et al.; AHA. Nonvalvular cardiovascular device-related infections. Circulation 108(16), 2015-2031 (2003).
8. Grossi P, Dalla Gasperina D, Pagani F, Marone P, Vigano M, Minoli L. Infectious complications in patients with the Novacor left ventricular assist system. Transplant. Proc. 33(1-2), 1969-1971 (2001).
9. Malani PN, Dyke DB, Pagani FD, Chenoweth CE. Nosocomial infections in left ventricular assist device recipients. Clin. Infect. Dis. 34(10), 1295-1300 (2002).
10. Mekontso-Dessap A, Kirsch M, Vermes E, Brun-Buisson C, Loisance D, Houel R. Nosocomial infections occurring during receipt of circulatory support with the paracorporeal ventricular assist system. Clin. Infect. Dis. 35(11), 1308-1315 (2002).
11. Slaughter MS, Rogers JG, Milano CA et al.; HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N. Engl. J. Med. 361(23), 2241-2251 (2009).
12. Topkara VK, Kondareddy S, Malik F et al. Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era. Ann. Thorac. Surg. 90(4), 1270-1277 (2010).
13. Schaffer JM, Allen JG, Weiss ES et al. Infectious complications after pulsatileflow and continuous-flow left ventricular assist device implantation. J. Heart Lung Transplant. 30(2), 164-174 (2011).
14. Hannan MM, Husain S, Mattner F et al.; International Society for Heart and Lung Transplantation. Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. J. Heart Lung Transplant. 30(4), 375-384 (2011).
15. Starling RC, Naka Y, Boyle AJ et al. Results of the post-U.S. Food and Drug Administration- approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J. Am. Coll. Cardiol. 57(19), 1890-1898 (2011).
16. Sharma V, Deo SV, Stulak JM et al. Driveline infections in left ventricular assist devices: implications for destination therapy. Ann. Thorac. Surg. 94(5), 1381-1386 (2012).
17. Raymond AL, Kfoury AG, Bishop CJ et al. Obesity and left ventricular assist device driveline exit site infection. ASAIO J. 56(1), 57-60 (2010).
18. Zierer A, Melby SJ, Voeller RK et al. Late-onset driveline infections: the Achilles' heel of prolonged left ventricular assist device support. Ann. Thorac. Surg. 84(2), 515-520 (2007).
19. Simon D, Fischer S, Grossman A et al. Left ventricular assist device-related infection: treatment and outcome. Clin. Infect. Dis. 40(8), 1108-1115 (2005).
20. Nurozler F, Argenziano M, Oz MC, Naka Y. Fungal left ventricular assist device endocarditis. Ann. Thorac. Surg. 71(2), 614-618 (2001).
21. Bomholt T, Moser C, Sander K et al. Driveline infections in patients supported with a HeartMate II: incidence, aetiology and outcome. Scand. Cardiovasc. J. 45(5), 273-278 (2011).
22. Chinn R, Dembitsky W, Eaton L et al. Multicenter experience: prevention and management of left ventricular assist device infections. ASAIO J. 51(4), 461-470 (2005).
23. Gordon RJ, Quagliarello B, Lowy FD. Ventricular assist device-related infections. Lancet Infect. Dis. 6(7), 426-437 (2006).
24. Matsumiya G, Nishimura M, Miyamoto Y, Sawa Y, Matsuda H. Successful treatment of Novacor pump pocket infection by omental transposition. Ann. Thorac. Surg. 75(1), 287-288 (2003).
25. Gordon SM, Schmitt SK, Jacobs M et al. Nosocomial bloodstream infections in patients with implantable left ventricular assist devices. Ann. Thorac. Surg. 72(3), 725-730 (2001).
26. Herrmann M, Weyand M, Greshake B et al. Left ventricular assist device infection is associated with increased mortality but is not a contraindication to transplantation. Circulation 95(4), 814-817 (1997).
27. Poston RS, Husain S, Sorce D et al. LVAD bloodstream infections: therapeutic rationale for transplantation after LVAD infection. J. Heart Lung Transplant. 22(8), 914-921 (2003).
28. Rose EA, Gelijns AC, Moskowitz AJ et al.; Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N. Engl. J. Med. 345(20), 1435-1443 (2001).
29. Toda K, Yonemoto Y, Fujita T et al. Risk analysis of bloodstream infection during long-term left ventricular assist device support. Ann. Thorac. Surg. 94(5), 1387-1393 (2012).
30. Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 49(1), 1-45 (2009).
31. Raad I, Hanna HA, Alakech B, Chatzinikolaou I, Johnson MM, Tarrand J. Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections. Ann. Intern. Med. 140(1), 18-25 (2004).
32. Bagdasarian NG, Malani AN, Pagani FD, Malani PN. Fungemia associated with left ventricular assist device support. J. Card. Surg. 24(6), 763-765 (2009).
33. Sinha P, Chen JM, Flannery M, Scully BE, Oz MC, Edwards NM. Infections during left ventricular assist device support do not affect posttransplant outcomes. Circulation 102(19 Suppl. 3), III194-III199 (2000).
34. Linneweber J, Dohmen PM, Kertzscher U et al. The effect of surface roughness on activation of the coagulation system and platelet adhesion in rotary blood pumps. Artif. Organs 31(5), 345-351 (2007).
35. Loforte A, Montalto A, Ranocchi F et al. Heartmate II axial-flow left ventricular assist system: management, clinical review and personal experience. J. Cardiovasc. Med. (Hagerstown) 10(10), 765-771 (2009).
36. Deng MC, Loebe M, El-Banayosy A et al. Mechanical circulatory support for advanced heart failure: effect of patient selection on outcome. Circulation 103(2), 231-237 (2001).
37. Baddour LM, Wilson WR, Bayer AS et al.; Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease; Council on Cardiovascular Disease in the Young; Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia; American Heart Association; Infectious Diseases Society of America. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111(23), e394-e434 (2005).
38. Walker PC, DePestel DD, Miles NA, Malani PN. Surgical infection prophylaxis for left ventricular assist device implantation. J. Card. Surg. 26(4), 440-443 (2011).
39. Engelman R, Shahian D, Shemin R et al.; Workforce on Evidence-Based Medicine, Society of Thoracic Surgeons. The Society of Thoracic Surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: Antibiotic choice. Ann. Thorac. Surg. 83(4), 1569-1576 (2007).
40. Skinner JL, Harris C, Aaron MF et al. Cost-benefit analysis of extended antifungal prophylaxis in ventricular assist devices. ASAIO J. 46(5), 587-589 (2000).
41. Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 101(25), 2916-2921 (2000).
42. Schulman AR, Martens TP, Russo MJ et al. Effect of left ventricular assist device infection on post-transplant outcomes. J. Heart Lung Transplant. 28(3), 237-242 (2009).
43. Shuhaiber J, Hur K, Gibbons R. Does the type of ventricular assisted device influence survival, infection, and rejection rates following heart transplantation? J. Card. Surg. 24(3), 250-255 (2009).
44. WL Holman. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). Birmingham, AL, USA 126(11), 1401-1406 (2012).
45. Goldstein DJ, el-Amir NG, Ashton RC Jr et al. Fungal infections in left ventricular assist device recipients. Incidence, prophylaxis, and treatment. ASAIO J. 41(4), 873-875 (1995).
46. Daneshmand MA, Rajagopal K, Lima B et al. Left ventricular assist device destination therapy versus extended criteria cardiac transplant. Ann. Thorac. Surg. 89(4), 1205-1209; discussion 1210 (2010).
47. Neragi-Miandoab S, Goldstein D, Bello R, Michler R, D'Alessandro D. Right ventricular dysfunction following continuous flow left ventricular assist device placement in 51 patients: predicators and outcomes. J. Cardiothorac. Surg. 7, 60 (2012).
48. Goldstein JA, Kern MJ. Percutaneous mechanical support for the failing right heart. Cardiol. Clin. 30(2), 303-310 (2012).
49. Bartoli CR, Dowling RD. The future of adult cardiac assist devices: novel systems and mechanical circulatory support strategies. Cardiol. Clin. 29(4), 559-582 (2011).